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Abstract
Background: In many developed countries, the treatment of hyperkinetic disorder (or ADHD)
consumes a considerable amount of resources. The primary aim of this study was to determine
change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in
Germany over time, and compare the cost with the cost of treatment for two physical disorders:
epilepsy and asthma.
Methods: The German Federal Statistical Office provided data on the direct cost of treating
hyperkinetic disorder, epilepsy and asthma in Germany for 2002, 2004, and 2006. The direct costs
of treatment incurred by hyperkinetic disorder in these years were compared with those incurred
by epilepsy and asthma.
Results: The total direct cost of treatment for the hyperkinetic disorder was € 177 million in 2002,
€ 234 million in 2004, and € 341 million in 2006. The largest proportion of the cost was incurred
by the age group < 15 years: € 158 million in 2002, € 205 million in 2004, and € 287 million in 2006.
The direct cost of treatment for epilepsy in this age group was a total of € 157 million in 2002, €
155 million in 2004, and € 155 million in 2006. For asthma, the total direct cost of treatment in this
age group was € 266 million in 2002, € 257 million in 2004, and € 272 million in 2006.
Conclusion: The direct cost of treatment for hyperkinetic disorder in the age group < 15 years
increased considerably between 2002 and 2006. Over the same period of time and for the same
age group, expenditure for epilepsy and asthma was more or less constant. The increase in
expenditure for the treatment of hyperkinetic disorder may be due to increasing demand for
diagnostic and therapeutic services and improved availability of such services. The study is limited
by the difficulty of obtaining consistent data on the direct cost of treatment for both physical and
psychiatric disorders in Germany.
Background
Hyperkinetic disorder (ICD-10) [1] or attention-deficit/
hyperactivity disorder (DSM-IV-TR) [2] is one of the most
common psychiatric disorders in childhood and adoles-
cence. The disorder is characterized by the core symptoms
attention deficit, hyperactivity and impulsivity. These core
symptoms occur as a continuous pattern and are inappro-
priate relative to the child's age, developmental stage and
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intelligence. They occur consistently and in various situa-
tions (e. g. at school, at home in the family, or whilst
together with peers) and lead to significant impairment in
the child's cognitive and psychosocial level of function-
ing, emotional well-being and quality of life [3-6].
In school-age children, the prevalence of this disorder is
reported to be 3–7% [2]. However, the prevalence rates
found in various studies differ considerably depending on
the particular classification system and diagnostic meth-
ods used [7]. The world-wide pooled prevalence has
recently been reported to be 5.29% [8]. Boys are two to
nine times more commonly affected than girls [2]. Hyper-
kinetic disorder may interfere with the daily life of
patients and their families to a greater degree than physi-
cal disorders such as asthma [9,10]. The long-term conse-
quences of ADHD include loss of productivity, healthcare
consumption, material damage, criminality, lost life
years, intangible and other costs [10,11].
Hyperkinetic disorder is usually treated using a multi-
modal treatment plan that may include interventions such
as behavioural therapy, parent counseling and/or medica-
tion [12-16]. In severe cases, hospitalization may be neces-
sary. In Germany, hospitalization rates vary from region to
region, depending on the availability of outpatient treat-
ment opportunities. In regions with a low density of office-
based physicians, hospitalization rates are higher than in
regions with a high density of office-based physicians [17].
Treatment of hyperkinetic disorder results in substantial
use of health care resources [10], on one hand through the
cost incurred on payers such as health insurance providers,
on the other through the additional financial burden
placed on patients and their families [18].
In many developed countries, the treatment of hyperki-
netic disorder (or ADHD) consumes a considerable
amount of resources. Attempts at determining the cost of
ADHD and the cost-effectiveness of various treatments for
ADHD have led to a range of results, some of which con-
cur whilst others are contradictory [14,15,17,19-25].
However, there is general agreement that ADHD has a
considerable impact both on direct and indirect costs
caused by the disorder. In health economic assessments,
costs are usually divided into direct and indirect costs
[11]. In these assessments, direct costs refer to consump-
tion of resources as a direct consequence of the disorder
(e. g. medical treatment), whilst indirect costs refer to
indirect consequences due to the disorder (e. g. the inabil-
ity to do work) and the resulting costs to society due to
loss of productivity. Whilst the direct costs of a disorder
are relatively easy to determine, the assessment of the
indirect costs may require the use of more or less elaborate
socio-economic models and calculations [11,17,18,26-
37].
Empirical data on the direct cost of treatment for hyperk-
inetic disorder have not been available for Germany.
Therefore, the main objective of this analysis was to deter-
mine the direct cost of treatment (CoT) associated with
hyperkinetic disorder in children and adolescents in Ger-
many, broken down by age and sex, and compare the
findings with the direct CoT of two fairly common physi-
cal disorders in childhood, namely epilepsy and asthma,
since such a comparison is demanded by public health
politicians in order to discuss allocation of financial
resources. A further objective of this analysis was to iden-
tify any changes in the direct CoT over time. Based on the
considerable increase in methylphenidate prescriptions as
well as increasing availability of evidence based behav-
ioural treatment programs and more inpatient and outpa-
tient treatment opportunities in Germany in the 1990s
[38], our expectation was that the total direct cost of treat-
ment would be seen to increase further over time, whilst
the increase in the total direct cost of treatment for epi-
lepsy and asthma would be much lower.
Methods
Data on the total direct cost of treatment for hyperkinetic
disorder, epilepsy and asthma were provided by the Ger-
man Federal Statistical Office (Statistisches Bundesamt)
for the years 2002, 2004, and 2006. These data are col-
lected on an annual basis by the Statistical Office from
health insurance providers and reported in summarized
form on a bi-annual basis [39]. The data reflect the cost of
treatment very well, as the data are based on the actual
expenditure of the health insurance providers [40]. The
Federal Statistical Office uses a top-down approach based
on data from hospitals, physicians' offices, rehabilitation
units, pharmacies etc. ("Krankheitskostenrechnung"). In
the bi-annual report, the data are broken down by diagno-
sis (in this case hyperkinetic disorder, epilepsy, and
asthma), age (age groups < 15 years, 15–30 years, 30–45
years, 45–65 years, 65–85 years, and over 85 years), sex,
and the various types of treatment (inpatient treatment,
outpatient treatment, medication, other treatments).
"Inpatient treatment" comprises hospital care and treat-
ment provided in a rehabilitation unit, "outpatient treat-
ment" comprises treatment by office-based physicians
and the cost of outpatient nursing care, "medication"
comprises cost for medication provided by retail pharma-
cies (excluding hospital pharmacies), and "other treat-
ment costs" comprise any other direct cost ultimately
reimbursed by health insurance providers such as medical
emergency services, auxiliary medical services, treatment
provided in a foreign country, or administrative costs. The
methodology on which the report is based accounts for
the primary diagnosis only and not for comorbid disor-
ders. However, if two equally important diagnoses are
reported, the costs of treatment are split equally among
the two diagnoses.Child and Adolescent Psychiatry and Mental Health 2009, 3:3 http://www.capmh.com/content/3/1/3
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As the data in the bi-annual report are not detailed
enough to carry out a comparison between hyperkinetic
disorder, epilepsy, and asthma in terms of direct cost of
treatment, we requested a sub-analysis from the German
Federal Statistical Office that allows this comparison.
Based on this sub-analysis, we compared descriptively the
direct cost of treatment for hyperkinetic disorder with the
direct cost of treatment for epilepsy and asthma.
Results
The total direct cost of treatment for the hyperkinetic dis-
order was   177 million in 2002,   234 million in 2004,
and   341 million in 2006. The largest proportion of the
cost was incurred by the age group < 15 years:   158 mil-
lion in 2002,   205 million in 2004, and   287 million in
2006. The direct cost of treatment for epilepsy in this age
group was a total of   157 million in 2002,   155 million
in 2004, and   155 million in 2006. For asthma, the total
direct cost of treatment in this age group was   266 mil-
lion in 2002,   257 million in 2004, and   272 million in
2006 (Table 1). As expected, the total direct cost of treat-
ment increased over time, whilst the change in the total
direct cost of treatment for epilepsy and asthma over the
same time period was negligible.
Approximately two thirds of the patients in this sample
treated for hyperkinetic disorder are in the age group < 15
years [41]. In 2002, a total of   128 million was incurred
by boys, and   31 million by girls in this age group. Pro-
portions were similar in the following years: in 2004 a
total of   167 million were incurred by boys and   38 mil-
lion by girls, and in 2006 a total of   237 million was
incurred by boys and   50 million by girls.
The greatest proportion of these costs resulted from inpa-
tient treatment. In 2002,   73 million (46.2% of the total
direct cost of treatment) resulted from inpatient treat-
ment, whilst   93 million (45.4% of the total direct cost
Table 1: Direct cost of treatment for hyperkinetic disorder, epilepsy, and asthma in Germany for the age group < 15 years, shown by 
diagnosis and type of treatment.
Diagnosis/Treatment Total cost of treatment for 2002 
in millions
Total cost of treatment for 2004 
in millions
Total cost of treatment for 2006 
in millions
Hyperkinetic disorder € 158 (100%) € 205 (100%) € 287 (100%)
Inpatient treatment € 73 (46.2%) € 93 (45.4%) € 112 (39.0%)
Outpatient treatment € 12 (7.6%) € 14 (6.8%) € 21 (7.3%)
Medication (outpatients) € 12 (7.6%) € 28 (13.7%) € 81 (28.2%)
Other treatment costs € 61 (38.6%) € 70 (34.2%) € 73 (25.4%)
Epilepsy € 157 (100%) € 155 (100%) € 155 (100%)
Inpatient treatment € 74 (47.1%) € 73 (47.1%) € 73 (47.1%)
Outpatient treatment € 9 (5.7%) € 8 (5.2%) € 9 (5.8%)
Medication (outpatients) € 22 (14.0%) € 24 (15.5%) € 24 (15.5%)
Other treatment costs € 52 (33.1%) € 50 (32.3%) € 49 (31.6%)
Asthma € 266 (100%) € 257 (100%) € 272 (100%)
Inpatient treatment € 92 (34.6%) € 83 (32.3%) € 82 (30.1%)
Outpatient treatment € 27 (10.2%) € 32 (12.5%) € 40 (14.7%)
Medication (outpatients) € 103 (38.7%) € 98 (38.1%) € 105 (38.6%)
Other treatment costs € 44 (16.5%) € 44 (17.1%) € 45 (16.5%)Child and Adolescent Psychiatry and Mental Health 2009, 3:3 http://www.capmh.com/content/3/1/3
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of treatment) resulted from inpatient treatment in 2004,
and   112 million (39.0% of the total direct cost of treat-
ment) resulted from inpatient treatment in 2006. A
smaller proportion of the total cost resulted from outpa-
tient treatment, medication, and other treatment costs
(Table 1).
The total direct cost of treatment resulting from patients
with epilepsy in the age group < 15 years was   157 mil-
lion in 2002,   155 million in 2004, and   155 million in
2006. The greatest proportion of these costs resulted from
inpatient treatment. The total direct cost of treatment for
asthma in the age group < 15 years was   266 million in
2002,   257 million in 2004, and   272 million in 2006.
The largest proportion of these costs were cost of medica-
tion (Table 1).
The direct cost of treatment for hyperkinetic disorder, epi-
lepsy, and asthma for the age group < 15 years and for the
years 2002, 2004 and 2006 is shown separately for males
and females in Table 2. The cost-ratio males to females
corresponds to the epidemiological-ratio of approxi-
mately 4:1.
Discussion
The total direct cost of treatment (CoT) for hyperkinetic dis-
order in the age group < 15 years in 2002 in Germany was
 177 million. In 2004, the total direct CoT was   234 mil-
lion, and in 2006   341 million. This considerable increase
in the total direct CoT may be explained by more extensive
use of opportunities to diagnose and treat the disorder,
resulting in a greater number of children and adolescents
being treated. Another possible explanation is that treat-
ment is increasingly becoming evidence-based and guide-
line oriented, resulting in longer courses of treatment and
greater amounts of medication being prescribed. It is
remarkable, that the cost of medication more than doubled
between 2002 and 2004, and more than doubled again
between 2004 and 2006. This marked increase in the
resources spent on medication to treat hyperkinetic disor-
der corresponds to earlier findings that showed a marked
increase in prescriptions of methylphenidate in the 1990s
in Germany [38]. However, the cost resulting from inpa-
tient treatment also increased. Comparing these costs with
the cost of treatment for epilepsy or asthma shows that the
costs incurred by treating these two physical disorders
remained fairly stable over the same period of time. This
applies to all types of treatment (inpatient treatment, out-
patient treatment, medication, other treatment costs). The
increase in costs for inpatient treatment for hyperkinetic
disorder may be explained by improved treatment oppor-
tunities, better treatment facilities with greater treatment
capacities, new and effective treatment approaches, and
increasing awareness of hyperkinetic disorder as a chal-
lenge to public health in Germany.
This marked increase in the cost of treatment for hyperki-
netic disorder has resulted in hyperkinetic disorder over-
taking asthma as the disorder with the greatest total direct
cost in the age group < 15 years in the year 2006. This was
not the case in 2002 and 2004, when asthma was the dis-
order with the greatest total direct cost in this age group by
a considerable margin.
As might be expected in face of the different prevalence of
hyperkinetic disorder in boys and girls, the total direct
cost due to the treatment of boys is indeed higher than the
cost due to the treatment of girls with hyperkinetic disor-
der (Table 2) and indicates that girls with ADHD need
similar financial resources as boys.
The data provided by the German Federal Statistical Office
on total direct cost of treatment can be compared with data
from other sources. One such source is the annual report on
prescriptions in Germany (Arzneiverordnungsreport, GKV-
Arzneimittelindex, Wissenschaftliches Institut der AOK)
that provides data on the number of prescriptions reim-
bursed by public health care providers, which comprise
approximately 90% of all patients (the remaining 10%
being privately insured). With this approach, the number
of prescriptions is multiplied by the cost of one Defined
Daily Dose (DDD) for a particular medication in order to
arrive at the direct cost of medication for a particular disor-
der. These reports also show a marked increase in expendi-
ture for medication used to treat hyperkinetic disorder,
mainly methylphenidate:   23.7 million in 2002,   51.4
million in 2004, and   108.8 million in 2006 [42-44].
Whilst this trend closely resembles the trend demonstrated
by data from the German Federal Statistical Office, there are
several discrepancies in terms of the direct cost resulting
from medication for hyperkinetic disorder. However, the
discrepancies can be explained by methodological differ-
ences between the approaches. The annual reports on pre-
scriptions in Germany have several limitations. First, the
data only reflect the cost incurred by 90% of the patients.
Secondly, the annual reports do not break down the costs
by age. This means that adults who receive methylpheni-
date prescriptions cannot be distinguished from children
and adolescents who receive similar prescriptions. Thirdly,
the data reflect costs incurred by a particular compound
rather than a particular disorder. Thus, the annual reports
on prescriptions reflect medication-related cost, whilst the
data provided by the German Federal Statistical Office
reflect disorder-related cost. As a given compound may
have more than one indication (e. g. methylphenidate for
both hyperkinetic disorder and narcolepsy), the annual
reports do not allow clear distinction between disorders
that happen to be treated with the same medication. In
turn, a given disorder may require treatment with several
different compounds, as is commonly the case in epilepsy
or asthma.Child and Adolescent Psychiatry and Mental Health 2009, 3:3 http://www.capmh.com/content/3/1/3
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The data provided by the German Federal Statistical Office
on total direct cost of treatment also has several limita-
tions due to the methodology by which they are collected
and analyzed. Although the data reflect the cost incurred
by 100% of the patients (both those with public and pri-
vate health insurance), the costs are broken down by the
following age groups: < 15 years, 15–30 years, 30–45
years, 45–65 years, 65–85 years, and over 85 years. As a
result, adolescents ≥ 15 years of age are in one group with
young adults. However, as the number of adolescents
treated for hyperkinetic disorder decreases dramatically
with age [41], the great majority of patients on medication
are in the age group < 15 years, with only a very small
number of adolescents ≥ 15 years of age being treated for
Table 2: Direct cost of treatment for hyperkinetic disorder, epilepsy, and asthma in Germany for the age group < 15 years, shown by 
type of cost and sex.
Treatment/
Diagnosis
Cost of treatment for 2002 in 
millions
Cost of treatment for 2004 in 
millions
Cost of treatment for 2006 in 
millions
males females males females males females
Inpatient 
treatment
Hyperkinetic 
disorder
€ 60 € 12 € 78 € 15 € 94 € 18
Epilepsy € 39 € 35 € 39 € 34 € 39 € 33
Asthma € 58 € 34 € 53 € 30 € 51 €31
Outpatient 
treatment
Hyperkinetic 
disorder
€  9 €  2€  1 0€  3€  1 6€  5
E p i l e p s y€  5€  4€  4€  4€  4€  4
Asthma € 17 € 10 € 20 € 12 € 26 € 14
Medication 
(outpatients)
Hyperkinetic 
disorder
€ 10 € 2 € 23 € 5 € 67 € 13
Epilepsy € 13 € 9 € 12 € 11 € 14 € 11
Asthma € 67 € 36 € 62 € 36 € 68 € 37
Other 
treatment costs
Hyperkinetic 
disorder
€ 49 € 15 € 56 € 15 € 60 € 14
Epilepsy € 29 € 23 € 30 € 21 € 28 € 22
Asthma € 28 € 16 € 27 € 17 € 27 € 18Child and Adolescent Psychiatry and Mental Health 2009, 3:3 http://www.capmh.com/content/3/1/3
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this disorder. These methodological differences in the
approaches explain the discrepancies in the two data sets.
This study has a number of limitations. Due to the type of
data collected by the German Federal Statistical Office and
the sources of these data (health insurance providers), the
data only reflect the direct cost of treatment, not the total
cost of hyperkinetic disorder to society. Another limita-
tion relates to the observation period. Because data were
available only for the years 2002, 2004, and 2006, it was
not possible to track the change in cost of treatment over
a longer period of time. Furthermore, it would have been
interesting to compare the direct cost of treatment for
hyperkinetic disorder with a broader range of both physi-
cal and psychiatric disorders. However, due to the limited
data available from the Statistical Office, the cost for treat-
ing hyperkinetic disorder could only be compared with
the cost for treating epilepsy and asthma. Finally, since the
study was carried out on the basis of data from the Ger-
man health care system, it is difficult to relate these find-
ings to the direct cost of treatment in other countries.
However, in the absence of other comparative data and
considering the difficulties involved in obtaining such
data, the findings from this study provide a rough approx-
imation of the total direct cost of treatment for hyperki-
netic disorder compared to epilepsy and asthma in an
industrialized country in Western Europe.
The increase in the direct cost of treatment for hyperki-
netic disorder runs parallel with recent improvement of
diagnostic capabilities and treatment options [14,45]. In
addition to child and adolescent psychiatrists, paediatri-
cians and general practitioners increasingly treat children
and adolescents with hyperkinetic disorder, one impor-
tant reason being that child and adolescent psychiatrists
alone are unable to meet the demand for all patients seek-
ing diagnostic assessment and treatment. Therefore, the
increase in cost incurred by medication for hyperkinetic
disorder is not surprising, as it reflects years of unmet need
[38,41] and indicates that an increasing number of chil-
dren and adolescents with hyperkinetic disorder are now
receiving an effective treatment. However, it remains to be
seen whether this increase in cost of treatment will con-
tinue at the present rate, especially since more expensive
long-acting medications have been introduced [14], or
whether costs will cease to increase as the number of
treated patients approaches the prevalence of hyperkinetic
disorder. In any case, the challenge of optimizing and
delivering cost-effective treatment for the individual
patient remains [45]. Two consensus-conferences have
resulted in the establishment of a central network for
ADHD in Germany. This network involves child and ado-
lescent psychiatrists, pediatricians, adult psychiatrists and
clinical psychologists [46]. Although such interdiscipli-
nary programs may potentially contribute to a further
increase the direct cost of treating hyperkinetic disorder,
improved treatment networks are likely to lead to a reduc-
tion in the indirect cost of the disorder, too. The direct and
indirect costs of treatment are likely to develop inversely,
thus reducing the total cost of the disorder to society in the
long run. Full economic evaluation would have to be
based on an analysis of cost-effectiveness (e. g. quality-
adjusted life years) and would require further data.
Conclusion
In summary, the results of this analysis support our expec-
tation that the total direct cost of treatment would
increase over time, whilst the increase in the total direct
cost of treatment for epilepsy and asthma would be much
lower. This shows that the gap caused by under-diagnosis
and under-treatment of hyperkinetic disorder in Germany
is closing. From a clinical point of view, this finding is
encouraging.
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